Drugs / BMS-823778
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01515202 | Mar → Sep 2012 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01666704 | Apr 2014 → Oct 2015 | atherosclerotic cardiovascular disease | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT01602367 | Jul → Nov 2012 | hypertensive disorder | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT01112423 | Jun → Dec 2010 | hyperlipidemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01111955 Comparator | Jul 2010 → Jan 2011 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-823778 | “Drug: BMS-823778” NCT01515202 ↗ |
| Action | Inhibit | “11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL4301600 ↗ |
| Modality | Small molecule | — CHEMBL4301600 ↗ |
| Route | Oral | “Capsules, Oral, 2 mg, once daily, 28 days” NCT01111955 ↗ |
| Target | HSD11B1 | “11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL4301600 ↗ |